About HepaRegeniX GmbH

HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.

Interested in
working for us?

Check out our latest job postings:



Board of Directors

Elias Papatheodorou, Chairman of the Board
Dr. Fabienne Roussel, Vesalius Biocapital
Prof. Dr. Johannes Zanzinger, BIVF
Dr. Emmanuelle Coutanceau, Novo Holdings A/S
Dr. Frank Hensel, High-Tech Gründerfonds (HTGF)